Daily Cardiology Research Analysis
Three impactful cardiology studies stood out today: a mechanistic JCI study links clonal hematopoiesis to aortic valve calcification via macrophage oncostatin M signaling; a cohort-scale functional genomics study in European Heart Journal reclassifies SCN5A variants in Brugada syndrome using automated patch clamp; and a PLoS Medicine cross-cohort analysis shows that even low-intensity smoking markedly increases cardiovascular risk while early cessation yields rapid benefits.
Summary
Three impactful cardiology studies stood out today: a mechanistic JCI study links clonal hematopoiesis to aortic valve calcification via macrophage oncostatin M signaling; a cohort-scale functional genomics study in European Heart Journal reclassifies SCN5A variants in Brugada syndrome using automated patch clamp; and a PLoS Medicine cross-cohort analysis shows that even low-intensity smoking markedly increases cardiovascular risk while early cessation yields rapid benefits.
Research Themes
- Mechanistic links between clonal hematopoiesis and valvular calcification
- Functional reclassification of cardiac ion channel variants
- Dose–response and cessation effects of cigarette smoking on cardiovascular outcomes
Selected Articles
1. Clonal hematopoiesis activates pro-calcific pathways in macrophages and promotes aortic valve stenosis.
Across large biobanks, clonal hematopoiesis, especially with TET2 or ASXL1 mutations, was associated with increased aortic valve stenosis risk. Mechanistically, TET2-deficient macrophages exhibited pro-inflammatory, pro-calcific programs and secreted oncostatin M that drove calcification in vitro; Tet2−/− marrow transfer augmented valve calcification in mice.
Impact: This study reveals a causal pathway linking clonal hematopoiesis to valve calcification via macrophage OSM signaling, opening avenues for biomarker-driven risk stratification and therapeutic targeting in calcific aortic valve disease.
Clinical Implications: Patients with CHIP, particularly TET2/ASXL1 mutations, may merit enhanced surveillance for aortic valve disease; macrophage-OSM axis inhibition could be explored as a disease-modifying strategy.
Key Findings
- CHIP increased AVS risk across All Of Us, BioVU, and UK Biobank, with stronger associations for TET2/ASXL1 mutations.
- scRNA-seq identified monocyte/macrophage pro-inflammatory, pro-calcific signatures with elevated oncostatin M in TET2-CH AVS patients.
- Conditioned media from TET2-silenced macrophages enhanced in vitro mesenchymal cell calcification, reversed by OSM silencing.
- Ldlr−/− mice receiving Tet2−/− bone marrow exhibited increased aortic valve calcium deposition.
Methodological Strengths
- Integrated human population genetics across multiple large biobanks with mechanistic validation.
- Multi-system approach combining scRNA-seq, in vitro macrophage–mesenchymal assays, and in vivo mouse bone marrow transplantation.
Limitations
- Observational human associations cannot fully exclude residual confounding.
- Human tissue and cellular experiments may have limited generalizability; precise sample sizes for each mechanistic arm were not detailed.
Future Directions: Prospective studies to evaluate CHIP-informed surveillance for AVS and interventional studies targeting the OSM pathway or CH clones to slow valve calcification.
Clonal hematopoiesis due to TET2-driver mutations (CH) is associated with coronary heart disease and worse prognosis among patients with aortic valve stenosis (AVS). However, it is unknown what role CH plays in the pathogenesis of AVS. In a meta-analysis of All Of Us, BioVU, and the UK Biobank, patients with CHIP exhibited an increased risk of AVS, with a higher risk among patients with TET2 or ASXL1 mutations. Single-cell RNA-sequencing of immune cells from AVS patients harboring TET2 CH-driver mutations revealed monocytes with heightened pro-inflammatory signatures and increased expression of pro-calcific paracrine signaling factors, most notably Oncostatin M (OSM). Secreted factors from TET2-silenced macrophages increased in vitro calcium deposition by mesenchymal cells, which was ablated by OSM silencing. Atheroprone Ldlr-/- mice receiving CH-mimicking Tet2-/- bone marrow transplants displayed greater calcium deposition in aortic valves. Together, these results demonstrate that monocytes with CH promote aortic valve calcification, and that patients with CH are at increased risk of AVS.
2. Automated patch clamp data improve variant classification and penetrance stratification for SCN5A-Brugada syndrome.
A calibrated, high-throughput automated patch clamp assay characterized 252 SCN5A variants from 3,335 Brugada patients, enabling ACMG-aligned reclassification of 110/225 VUS and linking loss-of-function severity to penetrance. Loss-of-function variants clustered in transmembrane pore regions, with the most severe variants showing ~25% penetrance and very high BrS enrichment.
Impact: This work operationalizes functional genomics at cohort scale to directly inform variant interpretation, enabling precision risk stratification in inherited arrhythmia.
Clinical Implications: Clinicians can leverage functional evidence to reclassify SCN5A VUS, refine BrS diagnosis, tailor family cascade testing, and align surveillance intensity with variant severity.
Key Findings
- 146/252 SCN5A variants were functionally abnormal; 100 showed severe loss-of-function (Z ≤ −4).
- Functional data enabled ACMG-based reclassification of 110/225 VUS (104 to likely pathogenic; 6 to likely benign).
- Loss-of-function variants localized predominantly to transmembrane pore regions; penetrance increased with functional deficit (Z ≤ −6: ~24.5% penetrance; OR ~501).
Methodological Strengths
- Calibrated high-throughput automated patch clamp with standardized Z-score framework mapped to ACMG PS3/BS3.
- Integration of functional data with population frequency, hotspots, case counts, and in silico predictors.
Limitations
- In vitro expression systems may not recapitulate all cellular contexts (e.g., trafficking, modifier genes).
- Penetrance estimates are derived from cohort frequencies, not prospective outcomes.
Future Directions: Extend APC frameworks to other arrhythmia genes, embed functional evidence in clinical pipelines, and prospectively validate penetrance and management algorithms.
BACKGROUND AND AIMS: Brugada Syndrome (BrS) is an inherited arrhythmia disorder that causes an elevated risk of sudden cardiac death. Approximately 20% of patients with BrS have rare variants in SCN5A, which encodes the cardiac sodium channel NaV1.5. Genetic workup of BrS is often complicated by SCN5A variants of uncertain significance (VUS) and/or incomplete penetrance. This study deployed an SCN5A-BrS functional assay at cohort scale to facilitate the implementation of genetic and precision medicine. METHODS: All 252 missense and in-frame insertion/deletion SCN5A variants from a previously published large cohort of BrS cases (n = 3335 patients) were analysed using a calibrated high-throughput automated patch-clamp (APC) assay. Variant functional Z-scores were assigned evidence levels ranging from BS3_moderate (normal function) to PS3_strong (loss-of-function), as defined by American College of Medical Genetics and Genomics criteria. Functional evidence was combined with population frequency, hotspot, case counts, protein-length changes, and in silico predictions. Odds ratios of BrS case-control enrichment and penetrance for BrS were calculated from variant frequencies in the BrS cohort and in gnomAD. RESULTS: Most variants (146/252) were functionally abnormal (Z ≤ -2), with 100 having severe loss-of-function (Z ≤ -4). Functional evidence enabled the reclassification of 110 of 225 VUS; 104 to likely pathogenic and 6 to likely benign. SCN5A variants with loss-of-function were mainly localized to the transmembrane domains, especially the regions comprising the central pore. SCN5A variant penetrance was proportional to the severity of loss-of-function; variants with Z ≤ -6 had penetrance of 24.5% (15.9%-37.7% CI) and an odds ratio of 501 for BrS. CONCLUSIONS: This cohort-scale APC dataset stratifies SCN5A variants found in BrS patients into normal function 'bystander' variants that have a low risk of BrS and loss-of-function variants that have a high risk for BrS. Functional data can be integrated with other criteria to reclassify a substantial fraction of VUS. The dataset helps clarify the SCN5A-BrS relationship and will improve the diagnosis and clinical management of BrS probands and their families.
3. Association between cigarette smoking status, intensity, and cessation duration with long-term incidence of nine cardiovascular and mortality outcomes: The Cross-Cohort Collaboration (CCC).
In 323,826 adults across 22 cohorts, even 2–5 cigarettes/day raised risks for multiple cardiovascular endpoints, and risk elevations were steepest at low exposure levels. The greatest risk reduction occurred within 10 years of cessation, with continued declines such that former smokers had >80% lower relative risk than current smokers by 20 years.
Impact: This large-scale, methodologically rigorous analysis quantifies risk at very low smoking intensities and underscores the outsized benefits of early cessation, sharpening prevention messaging and policy.
Clinical Implications: Clinicians should emphasize that ‘cutting down’ is not protective; even minimal smoking confers risk. Counseling should prioritize early cessation, with long-term benefits communicated to patients.
Key Findings
- Current smoking doubled all-cause mortality risk and substantially elevated CVD risk, with higher HRs in women.
- Low-intensity smoking (2–5 CPD) significantly increased risks for AF, HF, CVD mortality, and all-cause mortality.
- Risk rises were steepest at low exposure (first ~20 pack-years/CPD); cessation produced the largest risk reduction in the first 10 years, with >80% lower relative risk than current smokers at 20 years.
Methodological Strengths
- Very large pooled sample across 22 cohorts with long follow-up and spline modeling of nonlinearity.
- Extensive multivariable adjustment for demographic, socioeconomic, and cardiovascular risk factors.
Limitations
- Smoking exposure assessed at baseline only; potential misclassification may attenuate associations.
- No data on e-cigarettes or other tobacco products to assess dual/poly-use patterns.
Future Directions: Incorporate repeated exposure measures including vaping, evaluate cessation interventions by intensity and duration, and assess subgroup heterogeneity to inform tailored prevention.
BACKGROUND: Uncertainties persist regarding the precise shape of the smoking-outcome curves across various cardiovascular and mortality endpoints. This study aims to elucidate the relationships among smoking burden, intensity, and cessation duration across multiple cardiovascular outcomes. METHODS AND FINDINGS: Cox proportional hazard models were constructed to evaluate the association between pack-years, cigarettes per day (CPD), and years since cessation with cardiovascular outcomes in participants from 22 prospective cohort studies within the Cross-Cohort Collaboration Tobacco Working Group. We evaluated myocardial infarction (MI), stroke, coronary heart disease (CHD; MI, coronary revascularization, or coronary death), cardiovascular disease (CVD; stroke or cardiovascular death), heart failure (HF), atrial fibrillation (AFib), CHD mortality, CVD mortality, and all-cause mortality. Median follow-up varied across outcomes, with 14.4 years for MI (17,570 events), 19.3 years for CHD (30,625 events), 18.6 years for CVD (54,078 events), and approximately 19.4-19.9 years for mortality outcomes (CHD mortality: 17,429 events; CVD mortality: 33,120 events; all-cause mortality: 125,044 events). Spline terms were used to investigate the nonlinear association of continuous smoking/cessation measures with the examined outcomes. Models were adjusted for demographic, socioeconomic, and other cardiovascular risk factors. The study included 323,826 adults (148,635 non-mortality and 176,396 mortality outcomes with 25 and 16 million person-years at risk, respectively). Compared to never-smokers, current smokers had significantly increased risks for CVD (hazard ratio (HR) 1.74, 95% confidence intervals (CIs) [1.66,1.83] in men; HR 2.07, 95% CI [2.00,2.14] in women) and all-cause mortality (HR 2.17, 95% CI [2.09,2.25] in men; HR 2.43, 95% CI [2.38,2.48] in women; all p < 0.001). Compared with never-smokers, participants with 2-5 CPD demonstrated substantially elevated cardiovascular risks, with HR ranging from 1.26 (95% CI [1.09,1.45], p = 0.002) for AFib to 1.57 (95% CI [1.39,1.78], p < 0.001) for HF. Smoking 2-5 CPD was associated with increased CVD mortality (HR 1.57, 95% CI [1.41,1.75]), and all-cause mortality (HR 1.60, 95% CI [1.52,1.69]; both p < 0.001). Smoking 11-15 CPD conferred a higher risk of CVD (HR 1.87, 95% CI [1.69,2.06]) and all-cause mortality (HR 2.30, 95% CI [2.14,2.47]; both p < 0.001). The increased risk associated with the evaluated outcomes was steeper for the initial 20 pack-years and 20 CPD, respectively, compared to further smoking exposure. The most substantial reduction in risk across all outcomes was observed within the first 10 years after smoking cessation. However, the progressive risk reduction continues over extended time periods, with former smokers demonstrating over 80% lower relative risk than those of current smokers within 20 years of cessation. Limitations include potential exposure misclassification due to reliance on single baseline self-reported smoking measurements with extended follow-up periods, which may underestimate true risk associations, and lack of data on other tobacco products and electronic nicotine delivery systems, preventing analysis of dual- and poly-use patterns. CONCLUSION: Lower-intensity smoking is associated with cardiovascular risk and the primary public health message for current smokers should be early cessation, rather than reducing the amount of smoking. Cessation provides substantial immediate risk reduction, although risk continues to decrease significantly for the following two decades.